Company Overview and News
It makes a strategic buyout opportunity for anyone striving to achieve a vertically integrated model with cutting-edge product portfolio.
On today’s episode of Free Lunch, Associate Stock Strategist Ryan McQueeney recaps an action-packed weekend at the G-7 conference and prepares investors for what is to come this week as President Trump gears up to meet North Korean leader Kim Jung Un. Later, he discusses the near-term outlook for Applied Optoelectronics (AAOI - Free Report) .
Applied Optoelectronics Inc (NASDAQ:AAOI) is falling 6% on a negative write-up from Rosenblatt Securities where they post a “sell” rating and lower price target to $30 per share. Luckily, the stock came into this morning up 20% year-to-date. So a small dip won’t kill the momentum.
83GK MU 84GK AAOI
It seems like a major short covering is underway and it's probably going to be rewarding for long-side investors if they stay invested in the name.
Applied Optoelectronics (AAOI) is breaking out higher as the company sees an uptick in demand for its 100G transceiver products. Moreover, AAOI is aggressively cutting its manufacturing costs in an effort to increasing its bottom-line results. Its share price is gaining upward momentum following the improving operational results. I am buying stock in this name as its fundamental backdrop fuels share price gains.
Infinera (INFN) posted a yet another fantastic earnings report; it managed to beat the street's revenue and EPS estimates once again. But in spite of posting upbeat Q1 results, its shares are down by almost 15% since the results were announced. It seems like new challenges have emerged for Infinera Corporation that can potentially hamper its growth over the coming quarters. Let's take a look at the company's latest earnings report on a granular level to have a better understanding of its evolved financial position.
Investors may have gotten to enjoy a long weekend away from the stock market, but that joy didn’t last long. Due to political worries in Italy, U.S. stocks took it on the chin Tuesday. There were some strong performers, but by and large stocks declined. Here are our top stock trades going forward.
QQQ AMZN JPM AAPL AAOI NFLX MOMO NVDA
The likelihood of Applied Optoelectronics' (AAOI) return to growth has been a subject of several heated debates in investing forums and in the comments threads of many of my past articles on the name. Some perma-bears may believe that the company is on a downward spiral but that's not necessarily a done deal. Instead, it seems like institutional investors and analysts are growing bullish on the name.
FB AMZN AAOI
Known for its popular lawn and garden care products, Scotts Miracle-Gro Co. (SMG - Free Report) is one of the most recognized names in the gardening industry. Its U.S. brands include Scotts, Miracle-Gro, Ortho, and Smith & Hawken. The company’s customers are wide-ranging, from home improvement centers and hardware chains to nurseries and specialty crop growers.
ABBV AAOI ABBV TTD SMG
Farmer Bros (FARM - Free Report) , a Zacks Rank #5 (Strong Sell) is in the business of roasting, packaging and distributing coffee and allied products to restaurants, hotels, hospitals, convenience stores and fast food outlets. The company's primary raw material is green coffee. Green coffee is purchased through domestic commodity brokers.
2017-10-02 - Asif
Applied Optoelectronics is a leading, vertically integrated provider of fiber-optic networking products, primarily for four networking end-markets: internet data center, cable television, or CATV, fiber-to-the-home, or FTTH, and telecommunication, or telecom. The company design and manufacture a range of optical communications products at varying levels of integration, from components, subassemblies and modules to complete turn-key equipment. In designing products for its customers, Applied Optoelectronics begins with the fundamental building blocks of lasers and laser components. From these foundational products, the company design and manufacture a wide range of products to meet its customers’ needs and specifications, and such products differ from each other by their end market, intended use and level of integration. The company primarily focused on the higher-performance segments within all four of its target markets, which increasingly demand faster connectivity and innovat...
7h - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
8h - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET